In a Phase 1 trial of 17 patients with R/R B-ALL, bispecific CD19/CD22 CAR T-cells achieved a 100% response rate, with 88% of patients achieving MRD-negative CR [6]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.